With new hope for a two-year reimbursement extension for Omidria, Jason McCarthy now bets on 58% in return potential for the stock.
Alex Arfaei notes he continues to be the “lone bear” on this biotech player- especially after lead pipeline asset Rova-T is no longer looking at quick approval.
Jason McCarthy is out with bullish praise on SNGX now that the biotech player has won its second orphan designation for its RiVax asset.
Atossa Genetics Inc (NASDAQ:ATOS) investors are upbeat today upon news that this biotech player’s breast health program is getting an expansion. Specifically, the …
Cowen’s Eric Schmidt gives a vote of confidence to ADAP on back of yesterday’s fourth quarter financial and pipeline update.
Zosano Pharma Corp (NASDAQ:ZSAN) gave investors quite an encouraging update today: the drug maker has met a big clinical milestone in its long-term …
This analyst isn’t ready to get bullish on TEVA. Here’s why.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 17% …
Cantor’s Mara Goldstein says growth beyond 2020 for CELG just got cloudy with the FDA’s RTF letter for ozanimod.
What do you do when a company has “more debt than assets?” Maxim’s Jason Kolbert just lost patience with MNKD.
